WENDY CLARK: Open Payments
NPI 1902102536 · WINTER HAVEN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$708 in 44 payments from 14 companies in 2025. Trend: 2023 $355 · 2024 $624 · 2025 $708
Food & beverage: $708
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $146 |
| Alkermes, Inc. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $93 |
| ABBVIE INC. | 3 | $59 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $36 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
Products named: REXULTI, CAPLYTA, LYBALVI, VRAYLAR, INGREZZA, COBENFY, Auvelity, Dexcom G6 Transmitter.
Industry payments across FL — which companies pay providers there.
